Cellectis (NASDAQ:CLLS) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Friday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays cut their target price on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Stock Down 1.4 %

NASDAQ:CLLS opened at $2.10 on Friday. The business’s fifty day moving average price is $1.95 and its 200 day moving average price is $2.17. The firm has a market capitalization of $116.73 million, a price-to-earnings ratio of -1.62 and a beta of 3.10. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis has a 1-year low of $1.70 and a 1-year high of $3.77.

Cellectis (NASDAQ:CLLS) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The business had revenue of $18.05 million during the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same quarter in the prior year, the company earned ($0.31) EPS. On average, sell-side analysts forecast that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellectis

Several large investors have recently made changes to their positions in the company. Principal Financial Group Inc. raised its position in Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after acquiring an additional 12,467 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Cellectis during the 2nd quarter worth $29,000. Long Focus Capital Management LLC raised its holdings in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares in the last quarter. Finally, First Affirmative Financial Network acquired a new stake in shares of Cellectis in the 3rd quarter valued at $45,000. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.